All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair
Bookmark this article
The virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future.
AML Hub Satellite Symposium: Round table discussion and conclusions from the Chair
In this round table discussion chaired by Gert Ossenkoppele, Amsterdam University Medical Center, our experts, Charles Craddock, Jacquline Cloos, Adriano Venditti, and Christian Thiede answer questions from the audience and discuss the use of MRD as a surrogate for overall survival and the need for retrospective trials in this area. They also discuss the effectiveness of MRD in a maintenance setting, leukemic stem cells as a marker for MRD, and pivotal clinical trials in the field, some of which are ongoing.
More about...
Your opinion matters
1 vote - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox